LVADs, many patients still experience LVAD-specific complications such as stroke, infections (including driveline exit site or the LVAD pump itself), and device failure. 6-8 HeartMate 3 (HM3; Abbott Laboratories, Chicago, IL, USA) which is a fully magnetically levitated centrifugalflow pump, was developed as a next-generation LVAD. Several international trials have already demonstrated its superiority over previous axial-flow pumps for event-free survival. 9,10The clinical outcomes of LVADs with axial-flow pumps in Japanese cohorts were superior to those in other countries, 11,12 but the clinical results of new centrifugal LVAD remain to be evaluated. Herein, we demonstrate the short-term outcomes of HM3 implantation in comparison L eft ventricular assist devices (LVADs) provide improvements in survival and quality of life for patients with advanced heart failure (HF). 1,2 In the past decade, the indication for LVAD implantation has expanded not only as a bridge to transplantation (BTT) but also as destination therapy (DT) for patients ineligible for heart transplantation in the USA and Europe, and the clinical results in both BTT and DT patients have improved. [3][4][5] With technological advances, LVADs with continuous axial-flow pumps have been developed, making them smaller, with fewer moving parts (less biological reaction), and greater durability compared with the older models. 1,2 However, considering the prolonged support time of

We describe the case of a patient with a recurrent severe headache that occurred after heart transplant surgery. She was diagnosed with reversible cerebral vasoconstriction syndrome (RCVS) since typical imaging was seen through brain contrast computed tomography. Tacrolimus, an immunosuppressant, was suspected as the cause of the RCVS. The treatment was switched to cyclosporine, after which there was rapid improvement of her symptoms. This case highlights the importance of an immediate diagnosis to switch immunosuppressants to relieve symptoms and prevent progression to severe neurological dysfunction.